Skip to main content
European Commission logo
English English
CORDIS - EU research results
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Content archived on 2024-06-18

Prostate cancer: profiling and evaluation of ncRNA

Article Category

Article available in the following languages:

Novel markers for prostate cancer

Prostate cancer is the most frequent male cancer, accounting for 200 000 new cases every year. The PROSPER initiative investigated the expression and impact of non-coding RNAs on prostate cancer development and progression to improve diagnostics and identify new therapeutic targets.

Diagnosis of prostate cancer is largely based on testing positive for the prostate-specific antigen (PSA). This is increases the rate of over-detection without necessarily correlating with cancer symptoms. Apart from the role of androgens in the development of prostate cancer, the effect of molecular mechanisms such as non-coding ribonucleic acids (ncRNAs) is unknown. The EU-funded 'Prostate cancer: Profiling and evaluation of ncRNA' (PROSPER) project proposed to explore the role of ncRNAs (regulators of key cellular mechanisms) in prostate cancer. Project members will also evaluate the potential use of ncRNAs in diagnostic and prognostic tools as well as therapy targets. As a first step, scientists performed global microRNA (miRNA) expression analysis in prostate cancer samples, which led to the discovery of 20 novel miRNAs. Microarray analyses of miRNAs in over 180 prostate cancer samples indicated that androgens and/or the androgen receptor were instrumental in regulating expression of some miRNAs. Androgen signalling models verified the impact of androgen signalling on miRNA expression and also located androgen receptor binding sites near some of these miRNAs. For prognostic and diagnostic purposes, PROSPER scientists identified a panel of 25 and 56 miRNAs, respectively, to distinguish between normal and prostate cancer samples. miRNAs with oncogenic or tumour suppressor activity in prostate cancer were also identified. The prognostic and diagnostic miRNA panels developed during PROSPER could significantly improve the clinical diagnosis of prostate cancer and reduce unnecessary patient treatment. They also opened up new avenues for drug design and therapeutic exploitation.

Discover other articles in the same domain of application